CJC-1295 With or Without DAC: Why It Matters

Hormonal, Growth Hormone & Body Composition Research

There are two versions of CJC-1295, and they behave completely differently. Both are analogues of GRF 1-29, the active fragment of growth hormone releasing hormone, and a single modification separates them. Knowing which form you are working with is the starting point, and our product page states it plainly.

View product →

Findings

• CJC-1295 exists in two versions, with DAC and without, and they behave completely differently.
• With DAC it persists for days; without DAC, minutes, producing a brief pulse.
• The Vistara blend is the no-DAC form, stated plainly on the product page.
• The no-DAC form is also sold as Mod GRF 1-29, and each form pairs with its own body of literature.

DAC and no-DAC

DAC stands for Drug Affinity Complex. It is an addition to the molecule that lets it bind to serum albumin, and the consequence is a dramatic difference in how long the compound persists:

• CJC-1295 with DAC — albumin binding extends the half-life to the order of days. The signalling profile is long and flat.
• CJC-1295 without DAC — no albumin binding, a half-life measured in minutes, and a brief pulse-like profile. Also sold as Mod GRF 1-29.

Same name on the label, fundamentally different experimental tool. Each form pairs with its own body of literature, which is why the form matters.

Why it is blended with ipamorelin

CJC-1295 is a GHRH analogue: it acts at the growth hormone releasing hormone receptor. Ipamorelin is a secretagogue acting at the ghrelin receptor — a different receptor on a different pathway.

Pairing them is not about stacking two similar things. It is about engaging two separate signalling routes simultaneously, which allows researchers to examine interactions that are simply not observable when either compound is studied alone.

Ipamorelin earns its place in the pairing through selectivity. Earlier secretagogues acted broadly; ipamorelin is studied specifically because it acts narrowly, which makes the resulting data easier to attribute.

What Vistara Labs supplies

The CJC-1295 + Ipamorelin blend in this catalogue is the no-DAC form, the short-acting version with the pulse-like profile described above. It is supplied as a lyophilised powder in a sealed vial.

Certificates of analysis

A certificate of analysis records identity and purity, established analytically by an independent laboratory. Vistara Labs publishes certificates of analysis from independent laboratories for each compound, with purity above 99 percent, and the CJC-1295 (no DAC) and ipamorelin blend is listed on the lab reports page.

Reconstitution in a laboratory setting is typically performed with bacteriostatic water, with vials refrigerated and shielded from light thereafter.

Buying in Canada

Every order ships from within Canada, so there is no customs step. Vistara Labs delivers across the country with free shipping on larger orders, and current pricing is on the product page.

The other half of the comparison

Researchers examining GHRH-receptor activity frequently also work with tesamorelin, a GHRH analogue modified to resist enzymatic breakdown.

Reconstitution: the arithmetic for a 10 mg blend vial (2 mL of bacteriostatic water gives 5 mg/mL) is worked through on how much bacteriostatic water for CJC-1295 + Ipamorelin.

References

The published human CJC-1295 trial used the long-acting DAC analogue, not the no-DAC form. Ipamorelin has its own human pharmacokinetic study. No trial of the two combined was identified.

1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsTeichman SL et al. · J Clin Endocrinol Metab 2006 · PMID 16352683Randomised placebo-controlled trial in healthy adults — of the LONG-ACTING (DAC) CJC-1295 analogue, not the no-DAC form.
2. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersGobburu JV et al. · Pharm Res 1999 · PMID 10496658Human pharmacokinetic/pharmacodynamic study; five escalating infusion levels, eight healthy male subjects per level.

Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.